DDInter1938 DDInter1641
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993, A39994] the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States . Acne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne . Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Eliglustat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Vincristine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trametinib
Trametinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Eliglustat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Vincristine {u} (Compound) upregulates {v} (Gene) DHDDS
DHDDS {u} (Gene) is upregulated by {v} (Compound) Trametinib
Trametinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Vincristine {u} (Compound) downregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Trametinib
Trametinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rucaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Vincristine {u} (Compound) downregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is downregulated by {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rucaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarecycline
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Vincristine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trametinib (Compound) and Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Vincristine (Compound) upregulates DHDDS (Gene) and DHDDS (Gene) is upregulated by Trametinib (Compound) and Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Vincristine (Compound) downregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Trametinib (Compound) and Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Vincristine (Compound) downregulates DDIT4 (Gene) and DDIT4 (Gene) is downregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline